

Purpose: To implement a standard process for the management of children between 0 to < 5 years who have been in contact with an active TB case and ensure that follow-up is carried out according to the medical orders of the healthcare professionals involved during the window-period.

Objectives:

- a) Ensure use of the most effective prophylaxis for latent TB infection (LTBI) and in so doing, prevent the development of active TB disease.
- b) Ensure regular and optimal follow-up of patients who are undergoing treatment.
- c) Quickly identify any issues regarding compliance and offer the appropriate support.
- d) Rapidly detect the appearance of symptoms pointing to active TB and refer to physician.
- e) Quickly detect adverse reactions and ensure their management.

This order must be initialed by a physician at the time of the prescription of a TB treatment.

Notes: \rightarrow To reach out to the pneumologists:

- Pediatric pneumologist, write to: MCHTB &06CH_CUSM <u>MCHTB@MUHC.MCGILL.CA</u> or Zofia Zysman-Colman (Med) <u>zofia.zysman-colman.med@ssss.gouv.qc.ca</u>
- Adult pneumologist: Use SAFIR system : <u>Connect to SAFIR (gouv.qc.ca)</u> In case SAFIR is unavailable, write to: Faiz Ahmad Khan <u>faiz.ah-</u> <u>mad.khan.med@ssss.gouv.qc.ca</u> ou Richard Menzies, Dr. <u>dick.menzies@mcgill.ca</u>
- Pneumologist on call at the MUHC: 514 934-1934.

 \rightarrow Whenever a new LTBI diagnosis is made, you must notify the Public Health TB team (NRBHSS) at <u>tuberculose-santepublique.nrbhss@ssss.gouv.qc.ca</u>.

Important notes: - All individual medical prescriptions will have priority over the "Standard" follow-up described in this procedure.

- A specialized pediatric pneumologist should systematically be called in to manage cases involving children between 0 at < 5 years.

Instructions regarding use of the protocol

The following order, once signed and dated by the physician, will constitute a medical prescription for the tests and paraclinical exams required to enable the follow-up of patients. Nurses and physicians must check off and sign the boxes related to their specific tasks as soon as the prescribed actions are completed. Medication prescriptions, however, will be prepared on prescription sheets specifically for LTBI treatment.

Written by:	Dr. Latoya Campbell, UTHC and Dr. Élise Bélanger-Desjardins, IHC
	Dr. Jean-François Proulx and the NRBHSS infectious diseases team
	Dr. Faiz Ahmad Khan and Dr. David Zielinski, MUHC pneumologists
Revised by:	Dr. Valérie Messier and Aurélie Heurtebize (NRBHSS) on 2021-02-24
Approved by:	CMDPSF executive committee, IHC, 2021-04-26
	CMDPSF executive committee, UTHC, 2021-04-14



CONTACT WITH AN ACTIVE TB CASE 0 – < 5 YEARS FOLLOW-UP PROTOCOL – STANDARD MEDICAL ORDER RIFAMPICIN (RIF) • WINDOW/PERIOD

EMBOSSER ICI LA CARTE DU CSI OU CSTU, SI NON DISPONIBLE, INSCRIRE LES NOM, PRÉNOM, DATE DE NAISSANCE ET NUMÉRO DOSSIER EMBOSS HERE THE CARD OF IHC OR UTHC, IF NOT AVAILABLE, WRITE THE NAME, SURNAME, DATE OE RIETH AND EILE NI MARER

Date and When Who Interventions and investigations Signature Before prescribing RIF (window-period): Eliminate an active TB diagnosis (normal CXR and clinical investigations) Check for: 1 - Prior active TB □ Yes □ No Prior to 2 - Strain from the index case resistant to Rifampicin (RIF) □ Yes □ No treatment **Doctor** Note: - IF YES (1 and/or 2), reach out to the pneumologists¹ Signature - IF NO (1 and 2), prescribe the RIF window-period treatment ITL PRESC-YYYY/ MM/ DD MED-RIF-FENETRE EN □ Initial blood test : Liver function, creat., FSC Prescribe: □ Monthly F/up blood test : Liver function, creat. PRN² □ Check for any interactions with other drugs (e.g., Dilantin) with the pharmacist □ As per medical prescription above, take initial blood test : liver function, creat., FSC 1st day/date □ Initiate RIF as per medical prescription of the onset □ Notify the parent/tutor re. treatment, compliance, side effects Nurse Signature of Tx □ Prepare to complete follow-up forms: YYYY/ MM/ DD □ Compliance curve *ITL-COURBE-RIF* EN YYYY/ MM/ DD □ Registration of the medication *ITL-ENREG-MED-RIF EN* □ Monthly clinical assessment TB-ACT-ITL_EVAL-CLIN-MENS_EN **Regular monthly follow-up**: Notify the physician if abnormal. □ Medication follow-up and support to the patient: ITL-COURBE-RIF_EN and ITL-End of 1st ENREG-MED-RIF EN month of Tx Nurse Signature □ Monthly clinical assessment TB-ACT-ITL EVAL-CLIN-MENS EN YYYY/ MM/ DD YYYY/ MM/ DD □ As per medical prescription, take monthly F/up blood test: liver function, creat. PRN □ Perform TST³ following the window-period: See section 4 of the Clinical assessment of a suspected active TB case or a contact of active TB case DETECT-EVAL-CLIN_EN (already in the child's record) End of 2nd Nurse Signature □ TST< 5 mm and asymptomatic = notify the doctor and cease the treatment month of Tx YYYY/ MM/ DD as per medical prescription OR \Box TST \geq 5 mm or conversion⁴ or patient is symptomatic = notify the doctor End of If TST following the window-period is ≥ 5 mm or conversion³ or patient is windowsymptomatic : period² \Box Medical assessment \rightarrow If abnormal, reach out to the pneumologists¹ Doctor Signature YYYY/ MM/ DD In the absence of signs or symptoms of active TB : YYYY/ MM/ DD □ Prescribe the LTBI treatment *ITL PRESC-MED-RIF-FENETRE EN* □ Sign the LTBI protocol *ITL-PROT-SUIVI-RIF_EN* MD signature: License no.: Date: yvyy / mm / dd

¹ Contact information for pneumologists is provided on page 1 of this document.

² If symptomatic or abnormal results initial blood test.

³ The end of the window-period corresponds to 8 weeks after the last exposure to the index case. Exception: If the child is aged < 6 months, the treatment will be continued until he is 6 months old, at which point TST #2 will be done.

⁴ A conversion corresponds to an increase of ≥ 6 mm between the current TST and the prior TST, or a current TST ≥10 mm. (*DSPu-TB_ITL_PROT-SUIVI-RIF-FENETRE_EN, V2023-10-01*)